Nomura Holdings’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Nomura Holdings’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-8,333	Closed	-$96K	–	2930
2014 Q3	$96K	Hold	8,333	–	–	﹤0.01%	2554
2014 Q2	$160K	Sell	8,333 -2,500	-23%	-$44.1K	﹤0.01%	2444
2014 Q1	$200K	Buy	+10,833	New	+$178K	﹤0.01%	2343

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Nomura Holdings's CASC Position: Q3 2015 in Review

Nomura Holdings sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 23,150 shares — an estimated $522K sold.

Nomura Holdings first reported a position in CASC in Q2 2013 and held it in 8 quarters. The position peaked at $522K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

Nomura Holdings reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Nomura Holdings sold 23,150 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $522K.
Nomura Holdings first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 8 quarters.
Nomura Holdings's Cascadian Therapeutics, Inc. position peaked at $522K in Q2 2015.
93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on Nomura Holdings's 13F filing for Q3 2015, filed 16 Nov 2015.